

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/752,096	01/07/2004	Sabine Krause	DORRIE-0008	2246	
23599	7590 12/15/2006	12/15/2006		EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			JONES, DAMERON LEVEST		
2200 CLARE	NDON BLVD.				
SUITE 1400			ART UNIT	PAPER NUMBER	
ARLINGTON	ARLINGTON, VA 22201			1618	
	N.		DATE MAILED: 12/15/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

TY

Office Action Summary		Application No.	Applicant(s)		
		10/752,096	KRAUSE ET AL.		
		Examiner	Art Unit		
		D. L. Jones	1618		
Period fo	• •				
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE and the sign of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this communication. 0 (35 U.S.C. § 133).		
Status					
1)	Responsive to communication(s) filed on				
2a) <u></u> □	This action is FINAL . 2b) ☐ This	action is non-final.			
3)[3) Since this application is in condition for allowance except for formal matters, prosecution as to the merit				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims				
4) Claim(s) 1-48 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-48 are subject to restriction and/or election requirement.					
Applicati	on Papers				
10)	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correcti The oath or declaration is objected to by the Example.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	nder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te		

Art Unit: 1618

RESTRICTION INTO GROUPS

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-48, drawn to reagents and various methods thereof wherein the polybasic compound comprising the peptide is SEQ ID. Nos. 2, 3, 4, or 5, classified in class 424, subclass 1.69.

II. Claims 1-12, 16-24, 26-36, 38-43, and 45-48, drawn to reagents and various methods thereof wherein the polybasic compound comprising the peptide is not that as set forth in Group I above, classified in class 424, subclass 1.69.

Note: Claims appearing in more than one Group will only be examined to the extent that they read on the elected invention.

2. The inventions are distinct, each from the other because of the following reasons: Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions are distinguished from one another because the reagents of Group II are directed to peptides that have a different sequence from that of Group I. As a result a separate search of the art is necessary, even though the inventions classify in the same class/subclass. Furthermore, prior art which anticipates or renders obvious Group I would not necessary render obvious or anticipate species and uses thereof encompassed by Group II. Also, it is noted that while the compounds of Group II would

Art Unit: 1618

also require the presence of at least four arginine residues in the polybasic compound, the four arginine residues may be present in any combination (e.g., the arginine residues are not necessarily together, but may be spaced throughout the peptide sequence).

3. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art due to their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

ELECTION OF SPECIES

4. Claims 1-48 are generic to the following disclosed patentably distinct species comprising polybasic compounds comprising a peptide having at lease four arginine residues in any combination (i.e., the arginine residues are not necessarily side by side, but may appear throughout the sequence). Hence, various distinguish species are generated that are structurally different such that the species are independent or distinct. Applicant is required under 35 U.S.C. 121 to <u>elect a single disclosed species</u> <u>from within the elected group</u>, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon,

including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Note: Applicant is respectfully requested to identify a single peptide sequence for initial examination from within the elected group. In addition, Applicant is requested to identify the radiolabel binding moiety, the amino acid of human Platelet Factor 4 that are consistent with the elected species (see claim 4), and the polyvalent linker. Also, Applicant is requested to identify the claims that read on the elected species.

- 5. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

 MPEP § 809.02(a).
- 6. Due to the complexity of the restriction requirement, a telephone call was not made to request an oral election to the above restriction requirement.
- 7. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Art Unit: 1618

8. The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

- 9. Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.
- 10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. 3:15 p.m..

Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Primary Examiner
Art Unit 1618

December 11, 2006